2023-05-10 08:58:59 ET
- iTeos Therapeutics press release ( NASDAQ: ITOS ): Q1 GAAP EPS of -$0.44.
- The company’s cash, cash equivalents, and investments position was $706.6 million as of March 31, 2023, as compared to $824.0 million as of March 31, 2022.
- Research and Development (R&D) Expenses: R&D expenses were $25.6 million for the quarter ended March 31, 2023, as compared to $21.1 million for the same quarter of 2022.
- General and Administrative (G&A) Expenses: G&A expenses were $11.9 million for the quarter ended March 31, 2023, as compared to $10.6 million for the same quarter of 2022.
For further details see:
iTeos Therapeutics GAAP EPS of -$0.44